Merck believes India will fix ‘blatant’ patent violation
This article was originally published in Scrip
Executive Summary
Taken aback by what it claims is a "blatant violation" of its sitagliptin patent in India by Glenmark, Merck & Co has warned of a "degree of discomfort" in the global community as a result of such events while stressing that its India plans remain on course, at least for now.